☆ 4.8 Article

Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells

FRONTIERS IN IMMUNOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

A SIRPαFc Fusion Protein Conjugated With the Collagen-Binding Domain for Targeted Immunotherapy of Non-Small Cell Lung Cancer

Jiayang Liu et al.

Summary: The study aims to improve the tumor targeting and enhance the antitumor immune response of SIRP alpha Fc fusion protein through synthesizing a TKKTLRT-SIRP alpha Fc conjugate. The experiments demonstrate that the conjugate has a collagen-binding ability without affecting its CD47-binding affinity. In vivo distribution experiments show that the CBD-SIRP alpha Fc conjugate accumulates more effectively in tumor tissue compared to unmodified SIRP alpha Fc, leading to enhanced antitumor efficacy.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Immunology

An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade

Hongchuan Liu et al.

Summary: The fusion protein IL-21-alpha HSA demonstrated enhanced stability and prolonged half-life, resulting in significant anti-tumor efficacy. When used in combination with immune checkpoint blockades, it enhanced the cytotoxic activity of CD8(+) T and NK cells, leading to a long-term anti-tumor memory response.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Article Cell Biology

CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability

Xingzhe Ma et al.

Summary: Understanding the mechanisms of how T cells become dysfunctional in a tumor microenvironment is crucial for cancer immunotherapy. This study found that CD36 expression in tumor-infiltrating CD8(+) T cells, induced by TME cholesterol, is associated with tumor progression and poor survival, and that genetic ablation of Cd36 in these T cells leads to enhanced tumor eradication. Targeting CD36 or inhibiting ferroptosis could restore T cell function and enhance antitumor efficacy, especially in combination with anti-PD-1 antibodies.

CELL METABOLISM (2021)

添加到收藏夹

Review Engineering, Biomedical

Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy

Mengying He et al.

Summary: Immune checkpoint blockade therapy has shown potential efficacy in various cancers, but its effectiveness is limited when used alone. Studies have demonstrated that combining ICBT with other treatment modalities such as chemotherapy, radiotherapy, and phototherapy can enhance therapeutic outcomes. However, there are still challenges and potential issues that need to be addressed in the research on ICBT-based synergistic therapies.

ADVANCED HEALTHCARE MATERIALS (2021)

添加到收藏夹

Article Cell Biology

Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling

Juanjuan Yuan et al.

Summary: The study reveals the crucial role of LDLR in regulating the antitumor activity of CD8(+) T cells, including promoting T cell priming and clonal expansion, as well as regulating TCR signaling through interaction with the TCR complex. Moreover, the tumor microenvironment suppresses LDLR and TCR signaling in CD8(+) T cells via PCSK9, inhibiting the effector function of CTLs.

PROTEIN & CELL (2021)

添加到收藏夹

Article Oncology

TGF beta 1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism

Stefania Cane et al.

Summary: TGF beta 1 is an important target for cancer therapy, as selective targeting of TGF beta 1 can enhance the efficacy of cancer treatment and avoid cardiovascular toxicity.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Cell & Tissue Engineering

PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs

Meryl Roudaut et al.

Summary: PCSK9, a key regulator of LDL cholesterol metabolism, is found to be highly expressed in undifferentiated hiPSCs. Inhibition of PCSK9 in hiPSCs leads to decreased phosphorylation of SMAD2 and cell proliferation, while overexpression of PCSK9 stimulates cell proliferation by regulating the expression of DACT2, an endogenous inhibitor involved in TGF beta-R1 lysosomal degradation. This highlights a new role of PCSK9 in cellular proliferation and development.

STEM CELL REPORTS (2021)

添加到收藏夹

Article Oncology

PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma

Shi-Zhe Zhang et al.

Summary: The study revealed that high expression of PCSK9 in hepatocellular carcinoma (HCC) is associated with microvascular invasion and large tumor size, leading to poor overall survival and disease-free survival in patients. Experimental findings demonstrated that PCSK9 promotes HCC growth by inhibiting cell apoptosis, with FASN-mediated anti-apoptosis playing a significant role in this process.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Immunology

Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors

Shihao Xu et al.

Summary: The accumulation of lipids in the tumor microenvironment is associated with dysfunction of CD8(+) T cells, mediated in part by the CD36 receptor and its promotion of lipid uptake and peroxidation. Inhibiting p38 kinase or resolving lipid peroxidation may restore effector T cell functions and provide a potential therapeutic avenue for immunotherapies.

IMMUNITY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

PCSK9 Biology and Its Role in Atherothrombosis

Cristina Barale et al.

Summary: PCSK9 plays a key role in lipoprotein metabolism and atherosclerosis, with potential cardiovascular benefits from its inhibition. Currently, anti-PCSK9 antibodies and small interfering RNA are effective therapies to reduce LDL-C levels and attenuate cardiovascular disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Immunology

The cutting-edge progress of immune-checkpoint blockade in lung cancer

Fei Zhou et al.

Summary: The significant progress in immune checkpoint blockade has transformed the treatment paradigm for lung cancer patients, necessitating the exploration of additional predictive biomarkers for personalized immunotherapy. Managing acquired resistance to ICI treatment remains a formidable challenge, and a deeper understanding of the underlying biological mechanisms is crucial for overcoming these obstacles.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

Haiping Wang et al.

NATURE IMMUNOLOGY (2020)

添加到收藏夹

Review Immunology

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies

Florent Petitprez et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy

Jackie E. Bader et al.

MOLECULAR CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer

Gregoire de Streel et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity

Alison E. Ringel et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer

Xinjian Liu et al.

NATURE (2020)

添加到收藏夹

Article Oncology

α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by -TGF antibody to promote durable rejection and immunity in squamous cell carcinomas

E. Dodagatta-Marri et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Immunology

Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ

Chang Liu et al.

IMMUNITY (2019)

添加到收藏夹

Review Medicine, General & Internal

Immune Checkpoint Inhibitor Toxicities

Julian A. Marin-Acevedo et al.

MAYO CLINIC PROCEEDINGS (2019)

添加到收藏夹

Review Oncology

Treg-mediated acquired resistance to immune checkpoint inhibitors

Reem Saleh et al.

CANCER LETTERS (2019)

添加到收藏夹

Article Oncology

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

Hao Liu et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Medicine, Research & Experimental

CD36 tango in cancer: signaling pathways and functions

Jingchun Wang et al.

THERANOSTICS (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma

Xuyao Zhang et al.

APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2018)

添加到收藏夹

Article Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

添加到收藏夹

Article Immunology

Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor

Tomasz Maj et al.

NATURE IMMUNOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.